Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 67% of Pharmacies Have Demanded Premium for Generics Dispensing System
October 20, 2008
- Eli Lilly to Acquire ImClone for US$6.5 Billion
October 20, 2008
- Final Draft of Peptic Ulcer Guidelines Approved
October 20, 2008
- Novartis Enhances Sales/Marketing by Therapeutic Category
October 20, 2008
- Routine Use of PCV7 Is Cost-Effective: Wyeth
October 20, 2008
- BUSINESS NEWS IN BRIEF
October 20, 2008
- Japan's First ACS Patient Registry Study PACIFIC Underway
October 20, 2008
- Thalidomide to Be Approved for Multiple Myeloma
October 20, 2008
- Astellas Completes New Buildings in Its Tsukuba Research Center
October 20, 2008
- Industry Should Stress Contribution to Healthcare: Mr Kinoshita
October 20, 2008
- Kissei's Silodosin Approved in US
October 20, 2008
- To Promote Use of Generics or Cut Prices of Original Drugs?
October 20, 2008
- Otsuka Extends Joint Research Program with Galenea for 1 Year
October 20, 2008
- NEW PRODUCTS
October 20, 2008
- R&D NEWS IN BRIEF
October 20, 2008
- Teijin Acquires another Home Therapy Equipment Provider in US
October 20, 2008
- Mediceo Paltac, Alfresa to Merge to Create a \4 Trillion Wholesaler
October 20, 2008
- FALCO Signs CYP2D6*4 Gene Patent Licensing Agreement with LGC
October 20, 2008
- REGULATORY NEWS IN BRIEF
October 13, 2008
- NEW PRODUCTS
October 13, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…